Neurotech International • ASX:NTI
Focusing on the development and commercialisation of neurological solutions.
Overview
Neurotech International Ltd is a clinical-stage biopharmaceutical company focused on developing therapies for pediatric neurological and neurodevelopmental disorders, headquartered in Melbourne, Victoria. The company’s lead drug candidate, NTI164, is a non-intoxicating, pharmaceutical-grade oral cannabinoid therapy. Neurotech is advancing NTI164 for conditions such as Autism Spectrum Disorder (ASD), Rett syndrome, and PANDAS/PANS. In ASD, the company has completed Phase I/II and Phase II/III clinical studies that showed significant improvements in symptoms and caregiver-reported quality of life. Neurotech has received Human Research Ethics Committee approval to begin the pivotal Beyond Harmony Phase 3 clinical study in ASD Levels 2 and 3. For Rett syndrome, NTI164 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the US FDA, and the company is expanding its research on NTI164's mechanism of action. Additionally, Neurotech is conducting safety studies to support long-term clinical development and regulatory interactions in Australia and the United States.
Details
- Category
- Biotechnology Research
- Headquarters
- Melbourne, Victoria
- Type
- Public Company
- Founded
- 2016
- Followers
- 1,358
- Specialties
- Biomedical R&D, Product Development, Autism, Drug Development, Paediatric Neurology, Autism Spectum Disorder, Medical Research, Clinical Research, and Medical innovation
- Locations
- 55 Collins St Suite 102 / Level 1 Melbourne, Victoria 3000, AU
145 Stirling Highway Suite 5 CPC Nedlands, WA 6009, AU
Malta Life Sciences Park Block LS3, San Gwann, San Gwann SGN3000, MT